Table 3 Best-fitted vaccine efficacy profiles for the 6–12 weeks and 5–17 months cohorts when fitting to 3-month incidence data from the RTS,S Phase III trial
From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease
Cohort | Initial efficacy against infection at completion of 3rd dose (%) | Half-life of efficacy against infection (months) | Decay (Weibull decay shape parameter) | Boosting efficacy against infection at 4th dose (%) |
|---|---|---|---|---|
Exponential decay | ||||
6–12 weeks | 57.5 (95 % CI 40.1–71.2) | 7.4 (95 % CI 6.1–10.4) | Exponential | 48.5 (95 % CI 32.8–64.3) |
5–17 months | 72.5 (95 % CI 57.7–83.7) | 7.9 (95 % CI 6.1–11.0) | Exponential | 39.2 (95 % CI 30.6–53.4) |
Weibull decay | ||||
6–12 weeks | 64.9 (95 % CI 44.0–83.2) | 7.2 (95 % CI 6.0–9.8) | 0.84 (95 % CI 0.64–0.99) | 55.2 (95 % CI 34.5–73.1) |
5–17 months | 91.1 (95 % CI 74.5–99.7) | 7.32 (95 % CI 6.0–10.0) | 0.69 (95 % CI 0.54–0.9) | 49 (95 % CI 32–68.6) |